In the documents, Anvisa lists various types of data that it lacks, including mass trial results and quality assurances, saying that it does not have sufficient information to carry out a “positive benefit-versus-risk analysis of the vaccine.” The documents are ...
from Google Alert - health https://ift.tt/2QuttGq
via IFTTT
0 comments:
Post a Comment